T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the
bone marrow, mediastinum, central nervous system, and lymphoid organs. They account for …

Stigmasterol is a phytosterol derived from multiple herbaceous plants such as herbs,
soybean and tobacco, and it has received much attention for its various pharmacological …

Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that
accounts for 10–15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. The T-ALL event …

Hematological malignancies define a highly heterogeneous set of blood-, bone marrow-,
and organ-associated diseases with highly variable prognoses that constantly relapse upon …

Abstract ETP-ALL (Early T cell Progenitor Acute Lymphoblastic Leukemia) represents a high-
risk subtype of T cell acute lymphocytic leukemia (T-ALL). Therapeutically, ETP-ALL patients …

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the
uncontrolled proliferation of immature lymphoid cells. Over past decades, significant …

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits
the ubiquitin proteasome pathway that leads to the degradation of many intracellular …

T-cell malignancy is a broad term used for a diverse group of disease subtypes representing
dysfunctional malignant T cells transformed at various stages of their clonal evolution …

The identification of SERCA (sarco/endoplasmic reticulum calcium ATPase) as a target for
modulating gain-of-function NOTCH1 mutations in Notch-dependent cancers has spurred …

Although in the past three decades we welcomed the advent of targeted therapies in several
cancers, nelarabine, a purine nucleoside antimetabolite, remains the most recently …